

Form PTO-1594 (Rev. 10/02) OMB No. 0651-0027 (exp. 6/30/2005)

102313641

U.S. DEPARTMENT OF COMMERCE

OMB No. 0651-0027 (exp. 6/30/2005)	RKS ONLY U.S. Patent and Trademark Office
Tab settings ⇔⇔ ♥ ▼	T T T
To the Honorable Commissioner of Patents and Trademarks:	Please record the attached original documents or copy thereof.
1. Name of conveying party(ies): Bristol-Myers Squibb Pharma Company //- 25-12 Individual(s) General Partnership Corporation-State Other	2. Name and address of receiving party(ies) Name:Barr Laboratories, Inc. Internal Address: Street Address:_2 Quaker Road City:_PomonaState:_NY_Zip:_10970 Individual(s) citizenship
Additional name(s) of conveying party(ies) attached? Yes No 3. Nature of conveyance: Assignment Merger Security Agreement Change of Name Other Execution Date: 11/15/02	Association
4. Application number(s) or registration number(s): A. Trademark Application No.(s) Additional number(s) att	B. Trademark Registration No.(s) 1,945,277; 1,812,667 and 2,163,346 tached Yes No
Name and address of party to whom correspondence concerning document should be mailed: Name: Virginia R. Richard	6. Total number of applications and registrations involved:
Internal Address: Winston & Strawn	7. Total fee (37 CFR 3.41)\$_90.00 Enclosed Authorized to be charged to deposit account
Street Address: 200 Park Avenue	8. Deposit account number: 501-814
City: New York State: NY Zip:10166	
9. Signature.	THIS SPACE
Virginia R. Richard	November 21, 2002 gnature Date
Mail documents to be recorded with a	

Mail documents to be recorded with required cover sheet information to:
Commissioner of Patent & Trademarks, Box Assignments
Washington, D.C. 20231

00000131 1945277

01 FC:8521 02 FC:8522

12/16/2002 GTON11

40.00 OP 50.00 OP

EL544613408US



ASSIGNMENT OF TRADEMARKS

THIS ASSIGNMENT OF TRADEMARKS (this "Assignment") is made as of the 15th day of November, 2002, by and between Bristol-Myers Squibb Pharma Company, a Delaware partnership ("Assignor") and Barr Laboratories, Inc., a New York corporation ("Assignee").

WITNESSETH

WHEREAS, Assignor is engaged in manufacturing, distributing, marketing and selling products under the trademark Revia (the "Product"); and

WHEREAS, Assignor and Assignee have entered into an Asset Purchase Agreement for the Product dated as of the 15th day of November, 2002 (the "Asset Purchase Agreement"), pursuant to which Assignor is selling or causing to be sold to Assignee, and Assignee is purchasing and acquiring, among other things, certain assets connected with the Product, including right, title, and interest in and to those trade names, phone numbers; logos, common law trademarks, service marks, trademark and service mark registrations and applications, as set forth on such Schedule I annexed hereto (collectively, the "Trademarks");

NOW, THEREFORE, for good and valuable consideration the receipt and sufficiency of which are hereby acknowledged, Assignor does hereby sell, assign, transfer, set over, and deliver to Assignee right, title and interest in and to:

- (i) the Trademarks;
- (ii) the goodwill of Assignor's business connected with the use of the Trademarks;
- (iii) all rights of enforcement and the right to damages for past infringement, unfair competition or other conflicts relating to the Trademarks; and
- (iv) except as limited hereto and by the Asset Purchase Agreement, all other rights, including common law rights, relating to the Trademarks to the extent such rights exist.

FURTHERMORE, Assignor will, at the expense of Assignee (i) execute and deliver such further instruments including, without limitation, further instruments of assignment; and (ii) take such further actions as Assignee may reasonably request in order to register this Assignment at the appropriate registries and to demonstrate Assignee's title to the Trademarks or in order to prosecute any of the pending applications included in the Trademarks.

FURTHERMORE, for avoidance of doubt, Assignee acknowledges and agrees that neither Assignor nor Assignee makes any representations or warranties whatsoever with respect to the Trademarks and the other assets and rights described in clauses (ii), (iii) and (iv) above (including any representations and warranties with respect to the existence, validity, enforceability, use or ownership of any such common law rights), except for those

representations and warranties expressly set forth in Section 3.8 of the Asset Purchase Agreement.

This Assignment shall be governed by and construed in accordance with the laws of the State of New York, without regard to any applicable principles of conflicts of law.

[The next page is the signature page.]

	TNESS WHEREOF, r Rovia as of the date fin			executed	this	Assignment	of
BRISTOL-MYERS SQUIBB PHARMA COMPANY By: Name: Peter S. Ringrose, Ph.D. Title: President							
		BARR	R LABORATO	ORIES, INC	C.		

By:
Name: Martin Zeiger

Title: Senior Vice President

IN	WITNESS	WHEREOF,	the	parties	hereto	have	executed	this	Assignment	of
Trademarks for Revia as of the date first written above.									<u> </u>	

BRISTOL-MYERS SQUIBB PHARMA COMPANY

By:

Name: Peter S. Ringrose, Ph.D.

Title: President

BARR LABORATORIES, INC.

By:

Name: Martin Zeiger

Title: Senior Vice President

SCHEDULE I

ASSIGNED TRADEMARKS

Revia United States registered trademark – U.S. Registration No. 1945277; Serial No. 74572779

Revia United States registered trademark – U.S. Registration No. 1,812,667; Serial No. 74/204581

RECORDED: 11/25/2002

Revia Naltrexone HCl United States registered trademark – U.S. Registration No. 2,163,346; Serial No. 75/187094

Revia Canadian registered trademark – Canada Registration no. TMA463624; Application No. 0798102